Skip to main content

Table 4 Multivariate analysis of prognostic factors

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Variable

HR

95% CI

p value

GPS = 0

0.47

0.29–0.76

< 0.002

CEA ≤ 10 ng/mL

0.47

0.29–0.78

< 0.003

  1. CEA carcinoembryonic antigen, CI confidence interval, HR hazard ratio, GPS Glasgow prognostic score
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us